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One-year eye-to-eye comparison 
of wavefront-guided versus wavefront-optimized 
laser in situ keratomileusis in hyperopes
Christopher s sáles
edward e Manche
Byers eye institute, stanford 
University school of Medicine, 
Palo alto, Ca, Usa
Background: To compare wavefront (WF)-guided and WF-optimized laser in situ keratomileusis 
(LASIK) in hyperopes with respect to the parameters of safety, efficacy, predictability, refractive 
error, uncorrected distance visual acuity, corrected distance visual acuity, contrast sensitivity, 
and higher order aberrations.
Methods: Twenty-two eyes of eleven participants with hyperopia with or without astigmatism 
were prospectively randomized to receive WF-guided LASIK with the VISX CustomVue S4 
IR or WF-optimized LASIK with the WaveLight Allegretto Eye-Q 400 Hz. LASIK flaps were 
created using the 150-kHz IntraLase iFS. Evaluations included measurement of uncorrected 
distance visual acuity, corrected distance visual acuity, 5% and 25% contrast sensitivity, 
and WF aberrometry. Patients also completed a questionnaire detailing symptoms on a quan-
titative grading scale.
Results: There were no statistically significant differences between the groups for any of the 
variables studied after 12 months of follow-up (all P0.05).
Conclusion: This comparative case series of 11 subjects with hyperopia showed that WF-guided 
and WF-optimized LASIK had similar clinical outcomes at 12 months.
Keywords: wavefront, hyperopic, LASIK
Introduction
Hyperopic laser in situ keratomileusis (LASIK) technology has continued to evolve 
since its inception in the 1990s. Early, conventional approaches to treating hyperopia 
were effective at correcting simple spherocylinder refractive errors with good stability, 
but had the undesirable effect of inducing higher order aberrations (HOAs)1,2 by altering 
the cornea’s natural asphericity.3–5 Ameliorating this phenomenon has been the focus 
of developing more sophisticated wavefront (WF)-based ablation algorithms.
WF-based treatments can be classified into two broad categories: WF-optimized 
and WF-guided algorithms. The WF-optimized approach considers an eye’s refractive 
error and preoperative keratometry, in conjunction with the variable ablation depths 
of peripherally delivered laser pulses, to apply a precalculated aspheric ablation that 
aims to limit induced spherical aberrations. The WF-guided approach renders a cus-
tomized treatment plan based on an eye’s unique preoperative aberrometry with the 
intent of not only minimizing induced postoperative aberrations but also reducing or 
eliminating preoperative HOAs.
In this pilot, prospective, randomized, eye-to-eye comparison of hyperopes, we 
compared WF-guided to WF-optimized treatments. The primary outcome measures 
included uncorrected distance visual acuity (UDVA), refractive stability, refractive 
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predictability, contrast sensitivity, HOAs, loss of corrected 
distance visual acuity (CDVA), and a validated quantitative 
questionnaire.
Methods
Twenty-two eyes of eleven participants with hyperopia 
with or without astigmatism were randomized to receive 
either WF-guided LASIK with the VISX Star CustomVue 
S4 IR (Abbott Medical Optics Inc., Santa Ana, CA, USA) 
or WF-optimized LASIK with the WaveLight Allegretto 
Eye-Q 400 Hz (Alcon, Inc., Hüenberg, Switzerland) in 
their dominant eye and the alternative in their other eye. All 
participants provided their written informed consent after 
full disclosure of the nature of the research. The study was 
conducted at the Stanford University Eye Laser Center and 
adhered to the tenets of the Declaration of Helsinki as well 
as the Health Insurance Portability and Accountability Act. 
The authors (CSS and EEM) had no financial disclosures that 
might preclude objective conduct of the study.
Inclusion criteria included a stable refraction with a 
change of less than 0.50 diopters (D) of sphere or cylinder in 
the last year, best corrected visual acuity of 20/20 or better, 
age older than 21 years, and ability to participate in postop-
erative examinations for at least 12 months. Patients were 
excluded for use of rigid gas-permeable contact lenses; severe 
dry eye or blepharitis; corneal pathology (ie, recurrent erosion 
syndrome, basement membrane disease, keratoconus, and 
irregular corneal mires on central keratometry); pachymetry 
whereby the postoperative thickness would be less than 250 μm   
below the flap; baseline standard manifest refraction with 
a difference of 0.75 D or more in sphere power or 0.50 D   
in cylinder power as compared to the baseline standard 
cycloplegic refraction; history of herpes zoster or herpes sim-
plex; corneal warpage (ie, contact-lens induced topographical 
abnormalities); and certain systemic diseases or conditions 
(ie, connective tissue disease, diabetes, pregnancy, lactation, 
immunocompromised state, and severe atopy). Also excluded 
were patients with sensitivity to the study’s concomitant 
medications and patients participating in a clinical trial for 
another ophthalmic drug or device.
Patients who met the preceding criteria underwent a com-
prehensive preoperative evaluation, including a history, 5% 
and 25% contrast sensitivity (Precision Vision, La Salle, 
Illinois, USA), slit-lamp biomicroscopy, Goldmann applana-
tion tonometry, infrared pupillometry (Neuroptics, Irvine, CA, 
USA), dilated fundus examination, manifest and cycloplegic 
refraction using Early Treatment Diabetic Retinopathy Study 
charts, computerized corneal topography, and WF aberrometry 
using the VISX WaveScan aberrometer. Patients completed 
a questionnaire that has been employed and validated in pre-
vious contralateral eye studies.6–8 The questionnaire details 
symptoms quantified on a grading scale of 0 (no symptoms) 
to 10 (severe symptoms) for each of the following parameters: 
glare under night and day conditions, haze, halos, clarity 
under night and day conditions, dry eye symptom frequency 
and severity, foreign body sensation, vision fluctuation, and 
ghosting. Patients were also asked to grade their overall vision 
on a scale of 0 (excellent vision) to 10 (poor vision) as well as 
whether they preferred one eye to the other eye (Table 1). The 
LASIK surgeries were performed in a bilateral simultaneous 
fashion to negate any learning curve, and the questionnaire was 
administered preoperatively and postoperatively at months 1, 
3, 6, and 12.
WF aberrations were measured preoperatively and post-
operatively with a physiologic pupil under controlled scotopic 
conditions with the WaveScan aberrometer, which was also 
used to plan WF-guided treatments. All eyes had pupil sizes 
that measured 6 mm preoperatively and postoperatively. 
Although luminance was not measured, all aberrometry was 
performed in the same room. To account for the potential 
variability caused by measuring HOAs at different pupil 
diameters, aberrometry measurements that were taken when 
the pupil was within 0.25 mm of the preoperative diameter 
were used for data analysis. Six readings from each eye were 
taken at each visit before and after surgery when possible, 
and the best acquisition was used for analysis as determined 
by the clearest centroid image.
All surgeries were performed at Stanford University Eye 
Laser Center by a single surgeon (EEM). LASIK flaps were 
Table 1 Patient questionnaire
Parameter Scalea
glare, night none: 0 – Disabling: 10
glare, day none: 0 – Disabling: 10
haze none: 0 – Disabling: 10
halos none: 0 – Disabling: 10
Clarity, night no problem: 0 – Disabling: 10
Clarity, day no problem: 0 – Disabling: 10
Vision is excellent agree: 0 – Disagree: 10
Dry eye no problem: 0 – Disabling: 10
Dry eye severity no problem: 0 – Disabling: 10
Foreign body sensation never: 0 – always: 10
Vision fluctuates diurnally never: 0 – always: 10
Difficulty due to ghosting None: 0 – Extreme Difficulty: 10
Preferred eye same vs right vs leftb
Notes:  The validated questionnaire was completed preoperatively and postoperatively 
at months 1, 6, and 12. Participants completed the questionnaire for each eye. ascale 
was presented as discrete, whole numbers: 0, 1, 2 etc. bsubjects’ preferred eye was 
recoded into wavefront guided vs wavefront optimized for analysis.Clinical Ophthalmology 2014:8 submit your manuscript | www.dovepress.com
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created using the 150-kHz IntraLase iFS (Abbott Medical 
Optics Inc.). A 9.2 mm diameter, superior hinge with a 
105 μm programmed flap depth setting was used, and intra-
operative ultrasonic pachymetry (Sonogage, Cleveland, OH, 
USA) was performed in all cases. Patients were prospectively 
evaluated at 1 day, 1 week, 1 month, 3 months, 6 months, 
and 12 months; the data from evaluations performed at 1 day 
and 1 week are not presented.
Statistical analyses were performed with a commercially 
available software package (SPSS for Mac, Version 20.0; 
IBM Corporation, Armonk, NY, USA). Normal distribu-
tion of the preoperative and postoperative data was assessed 
by the Shapiro–Wilk test. All comparisons of means were 
performed using a Wilcoxon signed-rank test, which is the 
nonparametric analog of the paired t-test and is more accurate 
for a small sample size. Correlations between binary variables 
were calculated using McNemar’s exact test, which is an ana-
log of the chi-squared test and also considered more accurate 
for a small sample size. Correlations between multinomial 
categorical variables were calculated using the Monte Carlo 
test. All P-values were two sided and considered statistically 
significant when 0.05.
Results
Seven participants comprising 14 of the 22 eyes enrolled 
were female (63.6%). The mean age of the cohort was 
52.6±6.5 years (range, 40–60 years). The computer-
  generated schedule resulted in eight distance-dominant 
eyes randomized to the WF-guided group compared to three 
randomized to the WF-optimized group (72.7% [41.8–103.6] 
vs 27.3% [−3.6–58.2], P=0.03). Preoperative astigmatism 
ranged from 0.00 D to 2.50 D and sphere ranged from 0.00 D   
to 3.00 D. At baseline, there were no statistically significant 
differences between the WF-guided and WF-optimized 
groups for all studied parameters, including UDVA, con-
trast sensitivity, refractive error, and HOAs (all P0.05)   
(Table 2).
Efficacy and safety
There were no statistically significant differences between 
the WF-guided and WF-optimized groups at all postoperative 
months in mean UDVA and CDVA (all P0.05) (Table 2). 
The frequencies of achieving postoperative UDVA of 20/16 
or better, 20/20 or better, 20/30 or better, 20/40 or better, or 
20/50 or better were not statistically different between the 
groups (all P0.05) (Table 3, Figure 1A and B). Moreover, 
the frequencies with which the groups maintained their pre-
operative CDVA, lost one or two or more lines, or gained 
one or two or more lines after undergoing LASIK were not 
statistically different from each other either (all P0.05) 
(Table 3, Figure 1C and D).
Contrast sensitivity
There were no statistically significant differences in mean 
CDVA between the groups under 5% and 25% contrast 
sensitivity conditions at all postoperative time intervals 
studied (all P0.05) (Table 2). Five and twenty-five percent 
contrast sensitivity decreased less than one Early Treatment 
Diabetic Retinopathy Study line in the WF-guided group 
at 12 months compared to preoperative measurements, but 
these losses were not statistically significant (preoperative vs 
12 months: 5% contrast sensitivity, 0.19±0.09 vs 0.24±0.08 
logarithm of the minimal angle of resolution [logMAR] 
[Snellen equivalent of slightly worse than 20/30 vs slightly 
better than 20/35]; 25% contrast sensitivity, 0.17±0.06 vs 
0.24±0.08 logMAR [slightly better than 20/30 vs slightly 
better than 20/35]; P=0.30, P=0.09, respectively). In the 
WF-optimized group, 5% contrast sensitivity showed a sta-
tistically significant decrease of almost one Early Treatment 
Diabetic Retinopathy Study line at 12 months compared to 
preoperative measurements; 25% contrast sensitivity also 
decreased by less than one line, but did not reach statisti-
cal significance (preoperative vs 12 months: 5% contrast 
sensitivity, 0.18±0.10 vs 0.26±0.10 logMAR [slightly worse 
than 20/30 vs slightly worse than 20/35]; 25% contrast 
sensitivity, 0.19±0.07 vs 0.25±0.14 logMAR [slightly worse 
than 20/30 vs slightly better than 20/35]; P=0.04, P=0.14, 
respectively).
refractive error, predictability,  
and stability
There were no statistically significant differences in mean 
sphere or spherical equivalent (SE) at all postoperative 
months (all P0.05) (Table 2, Figure 1E and F). At all inter-
vals studied, there were also no statistically significant differ-
ences between the groups with regard to the frequency that 
each achieved an SE within ±0.25 D, ±0.50 D, and ±1.00 D 
of emmetropia (all P0.05); there was, however, a trend that 
failed to reach statistical significance favoring approximately a   
40% higher frequency of attaining a refraction within ±0.25 D   
of emmetropia in the WF-guided group at postoperative 
month 12 (81.8% [48.2–97.7] vs 36.4% [10.9–69.2]; P=0.13) 
(Table 3, Figure 2A and B). There was no statistically sig-
nificant difference in the proportion of each group to have 
an SE change of more than 0.50 D between months 3 and 
12 (Figure 2E and F).Clinical Ophthalmology 2014:8 submit your manuscript | www.dovepress.com
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Table 2 Preoperative and postoperative parameters comparing WF-optimized to WF-guided hyperopic lasiK
Parameter Mean ± standard deviation, range Pa
WF-guided (n=11) WF-optimized (n=11)
Preoperative
UDVab 0.36±0.25, −0.10 to 0.80 0.40±0.20, 0.10 to 0.80 0.56
CDVab −0.15±0.05, −0.20 to −0.10 −0.15±0.07, −0.20 to 0.00 1.00
CDVab 5% contrast 0.19±0.09, 0.10 to 0.40 0.18±0.10, 0.00 to 0.30 0.43
CDVab 25% contrast 0.17±0.06, 0.10 to 0.30 0.19±0.07, 0.10 to 0.30 0.60
sphere (D) 1.30±0.81, 0.00 to 3.00 1.61±0.66, 0.25 to 2.75 0.23
astigmatism (D) 0.86±0.63, 0.00 to 2.50 0.64±0.57, 0.00 to 2.00 0.12
spherical equivalent (D) 1.73±0.66, 0.88 to 3.38 1.93±0.64, 1.25 to 3.25 0.68
Coma 0.21±0.15, 0.06 to 0.60 0.18±0.13, 0.05 to 0.47 0.48
Trefoil 0.13±0.09, 0.04 to 0.31 0.14±0.10, 0.04 to 0.38 0.61
rMs error (μm) 0.35±0.15, 0.17 to 0.72 0.36±0.17, 0.09 to 0.59 0.93
Postoperative month 1
UDVab −0.06±0.15, −0.20 to 0.20 −0.05±0.17, −0.20 to 0.40 1.00
CDVab −0.16±0.09, −0.30 to 0.00 −0.14±0.09, −0.20 to 0.00 0.46
CDVab 5% contrast 0.23±0.09, 0.10 to 0.40 0.25±0.08, 0.10 to 0.40 0.83
CDVab 25% contrast 0.19±0.08, 0.10 to 0.40 0.22±0.10, 0.10 to 0.40 0.75
sphere (D) −0.41±0.36, −1.00 to 0.00 −0.41±0.32, −1.25 to 0.00 1.00
astigmatism (D) 0.25±0.39, 0.00 to 1.25 0.45±0.38, 0.00 to 1.00 0.32
spherical equivalent (D) −0.30±0.26, −0.75 to 0.12 −0.18±0.29, −0.75 to 0.25 0.23
Coma 0.13±0.08, 0.00 to 0.26 0.16±0.09, 0.04 to 0.29 0.37
Trefoil 0.10±0.05, 0.04 to 0.17 0.14±0.12, 0.01 to 0.41 0.28
rMs error (μm) 0.23±0.06, 0.12 to 0.32 0.28±0.11, 0.15 to 0.50 0.15
Postoperative month 3
UDVab −0.10±0.21, −0.30 to 0.40 −0.11±0.13, −0.20 to 0.20 1.00
CDVab −0.19±0.10, −0.30 to 0.00 −0.16±0.05, −0.20 to −0.10 0.72
CDVab 5% contrast 0.22±0.09, 0.10 to 0.40 0.24±0.08, 0.10 to 0.40 0.86
CDVab 25% contrast 0.20±0.12, 0.10 to 0.50 0.20±0.07, 0.10 to 0.30 1.00
sphere (D) −0.28±0.28, −0.75 to 0.25 −0.45±0.35, −1.25 to 0.00 0.30
astigmatism (D) 0.20±0.26, 0.00 to 0.75 0.30±0.33, 0.00 to 0.75 0.49
spherical equivalent (D) −0.18±0.25, −0.62 to 0.25 −0.30±0.29, −0.88 to 0.12 0.40
Coma 0.15±0.13, 0.05 to 0.51 0.16±0.11, 0.03 to 0.39 0.77
Trefoil 0.09±0.04, 0.03 to 0.17 0.11±0.06, 0.02 to 0.22 0.23
rMs error (μm) 0.23±0.13, 0.10 to 0.55 0.28±0.13, 0.10 to 0.53 0.16
Postoperative month 6
UDVab −0.13±0.11, −0.30 to 0.10 −0.08±0.13, −0.20 to 0.20 0.52
CDVab −0.17±0.10, −0.30 to 0.00 −0.18±0.06, −0.30 to −0.10 0.93
CDVab 5% contrast 0.19±0.07, 0.10 to 0.30 0.21±0.07, 0.10 to 0.30 0.67
CDVab 25% contrast 0.19±0.10, 0.10 to 0.40 0.20±0.09, 0.10 to 0.30 0.95
sphere (D) −0.25±0.33, −0.75 to 0.50 −0.41±0.23, −0.75 to 0.00 0.20
astigmatism (D) 0.14±0.17, 0.00 to 0.50 0.34±0.26, 0.00 to 0.75 0.07
spherical equivalent (D) −0.16±0.36, −0.62 to 0.75 −0.24±0.26, −0.62 to 0.25 0.34
Coma 0.15±0.09, 0.02 to 0.33 0.15±0.15, 0.02 to 0.42 0.64
Trefoil 0.11±0.06, 0.03 to 0.21 0.11±0.06, 0.01 to 0.20 0.70
rMs error (μm) 0.25±0.08, 0.09 to 0.38 0.29±0.14, 0.11 to 0.52 0.33
Postoperative month 12
UDVab −0.11±0.09, −0.30 to 0.00 −0.08±0.12, −0.20 to 0.20 1.00
CDVab −0.18±0.08, −0.30 to 0.10 −0.15±0.07, −0.20 to 0.00 0.43
CDVab 5% contrast 0.24±0.08, 0.10 to 0.40 0.26±0.10, 0.20 to 0.50 0.60
CDVab 25% contrast 0.24±0.08, 0.10 to 0.40 0.25±0.14, 0.10 to 0.50 1.00
sphere (D) −0.23±0.31, −0.75 to 0.50 −0.25±0.47, −0.75 to 0.50 0.89
astigmatism (D) 0.20±0.27, 0.00 to 0.75 0.23±0.33, −0.25 to 0.75 1.00
spherical equivalent (D) −0.12±0.32, −0.75 to 0.50 −0.11±0.46, −0.75 to 0.62 0.90
Coma 0.18±0.12, 0.02 to 0.42 0.19±0.14, 0.05 to 0.47 0.64
Trefoil 0.09±0.04, 0.05 to 0.19 0.11±0.05, 0.02 to 0.18 0.28
rMs error (μm) 0.26±0.10, 0.13 to 0.45 0.29±0.13, 0.13 to 0.53 0.44
Notes: aP-values for means are by paired Wilcoxon signed-rank test for nonparametrically distributed data from a small sample. bVisual acuities are by logarithm of the 
minimal angle of resolution.
Abbreviations: CDVa, corrected distance visual acuity; D, diopter; lasiK, laser in situ keratomileusis; rMs, root mean square; UDVa, uncorrected distance visual acuity; 
WF, wavefront.Clinical Ophthalmology 2014:8 submit your manuscript | www.dovepress.com
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Figure 1 Comparison of WF-guided lasiK and WF-optimized lasiK standard graphs.
Notes: (A) Uncorrected visual acuity outcomes of WF-guided lasiK at 12 months. (B) Uncorrected visual acuity outcomes of WF-optimized lasiK at 12 months. 
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Abbreviations: CDVa, corrected distance visual acuity; D, diopter; lasiK, laser in situ keratomileusis; Preop, preoperative; Postop, postoperative; UDVa, uncorrected 
distance visual acuity; WF, wavefront.
There was a trend favoring almost one quarter D less astig-
matism in the WF-guided group compared to the WF-optimized 
group that did not reach statistical significance at postoperative 
month 6 (0.14±0.17 D vs 0.34±0.26 D; P=0.07), but this trend 
did not persist at 12 months (0.20±0.27 D vs 0.23±0.33 D; 
P=1.00) (Table 2). At 12 months there were also no differences 
in the frequencies with which each group achieved astigma-
tism 0.50 D and 1.00 D (P0.05) (Figure 2C and D).Clinical Ophthalmology 2014:8 submit your manuscript | www.dovepress.com
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higher order aberrations
There were no statistically significant differences in coma, 
trefoil, and higher order root mean square (RMS) error 
between the groups postoperatively (all P0.05). RMS error 
decreased in both WF-guided and WF-optimized groups at 
12 months compared to preoperative measurements, but 
neither of these changes reached statistical significance (pre-
operative vs 12 months: WF-guided, 0.35±0.15 vs 0.26±0.10 
points; WF-optimized, 0.36±0.17 μm vs 0.29±0.13 μm; 
P=0.07, P=0.13, respectively).
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subjective parameters
There were no statistically significant differences in sub-
jective parameters between the groups at postoperative 
month 12. However, there were trends that did not reach 
statistical significance for night and day clarity, which were 
approximately three-quarters of a severity point lower for 
both parameters in the WF-guided group compared to the 
WF-optimized group (night clarity, 0.82±0.98 vs 1.27±1.10 
points; day clarity, 0.82±0.87 vs 1.36±1.21 points; P=0.17, 
P=0.18, respectively). Participants more frequently preferred 
their WF-guided eye (45.5%) than their WF-optimized eye 
(9.1%), but this trend did not reach statistical significance 
either (P=0.20) (Table 4).
Discussion
Although it is only a limited series of 11 participants, to the 
best of our knowledge, this is the first eye-to-eye comparison 
of WF-guided and WF-optimized LASIK for the primary 
treatment of hyperopia. Among 22 eyes, WF-guided LASIK 
did not offer any statistically significant advantages over WF-
optimized LASIK for the parameters studied at postoperative 
months 1, 3, 6, and 12, including UDVA, CDVA, contrast 
sensitivity, astigmatism, SE, HOAs, efficacy, predictability, 
and safety (all P0.05). However, one must consider the 
alternative hypothesis that there was insufficient power to 
detect differences between the groups that are of potential 
clinical importance.
Previous studies have hypothesized that both WF-guided 
and WF-optimized LASIK in hyperopes may have an 
advantage with respect to preserving low-contrast sensitiv-
ity compared to conventional LASIK.9,10 Our results, which 
exhibited a decline in contrast sensitivity at 12 months from 
preoperative measurements in both groups, did not confirm 
this postulate (5% contrast sensitivity: WF-guided P=0.30, 
Table 4 Preoperative and 12 months postoperative questionnaire resultsa after WF-optimized and WF-guided hyperopic laser in situ 
keratomileusis
Parameter Mean ± standard deviation, range Pb
WF-guided (n=11) WF-optimized (n=11)
Preoperative
glare, night 1.64±2.29, 0–6 1.64±2.29, 0–6 1.00
glare, day 2.00±2.53, 0–7 2.00±2.53, 0–7 1.00
haze 1.82±2.71, 0–7 1.91±2.77, 0–7 1.00
halos 0.55±1.51, 0–5 0.55±1.51, 0–5 1.00
Clarity, night 3.45±2.94, 0–8 3.45±2.94, 0–8 1.00
Clarity, day 2.36±2.66, 0–8 2.45±2.70, 0–8 1.00
Vision is excellent 3.82±1.94, 1–8 4.36±2.34, 1–8 0.35
Dry eye 2.27±2.10, 0–5 2.27±1.90, 0–5 1.00
Dry eye severity 1.55±1.37, 0–3 1.73±1.27, 0–3 1.00
Foreign body sensation 1.00±1.79, 0–6 1.00±1.79, 0–6 1.00
Vision fluctuates diurnally 1.27±1.74, 0–5 1.36±1.86, 0–5 1.00
Difficulty due to ghosting 0.64±1.80, 0–6 0.64±1.80, 0–6 1.00
12 months postoperative
glare, night 1.45±1.86, 0–6 1.45±1.86, 0–6 1.00
glare, day 0.91±1.38, 0–4 0.91±1.38, 0–4 1.00
haze 0.91±1.14, 0–3 0.91±1.04, 0–3 1.00
halos 0.36±0.67, 0–2 0.55±0.82, 0–2 1.00
Clarity, night 0.82±0.98, 0–3 1.27±1.10, 0–3 0.17
Clarity, day 0.82±0.87, 0–2 1.36±1.21, 0–4 0.18
Vision is excellent 2.64±3.35, 0–8 3.00±2.65, 0–8 0.57
Dry eye 1.91±1.97, 0–7 1.91±1.97, 0–7 1.00
Dry eye severity 1.73±1.56, 0–5 1.73±1.56, 0–5 1.00
Foreign body sensation 0.73±1.27, 0–4 0.64±0.81, 0–2 1.00
Vision fluctuates diurnally 1.00±1.26, 0–3 1.18±1.54, 0–4 1.00
Difficulty due to ghosting 0.09±0.30, 0–1 0.36±1.21, 0–4 1.00
Percent, 95% confidence interval
Preferred eye 45.5c, 16.7–76.6 9.1c, 0.01–41.3 0.20d
Notes: aThe means presented are from participants’ responses to a validated questionnaire. The questionnaire was completed preoperatively and postoperatively at months 
1, 6, and 12. Participants completed the questionnaire for each eye. bP values for means are by paired Wilcoxon signed-rank test for nonparametrically distributed data from 
a small sample. c45.5% of subjects (10 eyes) responded “same”. dP values for proportions are by Monte Carlo chi-squared statistic for data from a small sample.
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WF-optimized P=0.04; 25% contrast sensitivity: WF-guided 
P=0.09, WF-optimized P=0.14). Moreover, comparison of 
the WF-guided and WF-optimized groups suggests that there 
was no difference in the extent to which they were associated 
with a decline in contrast sensitivity (5% contrast sensitivity 
P=0.60, 25% contrast sensitivity P=1.00).
Studies of myopes have concluded that WF-guided 
approaches may yield small, but statistically significant 
advantages in reducing total HOAs induced by laser ablation 
compared to WF-optimized approaches.11–14 Our series did 
not find such a difference in RMS error at 12 months nor 
did it detect a potential trend (P=0.44) raising the question 
of whether surgically induced higher order aberrations are 
affected differently by WF algorithms in hyperopes compared 
to myopes. Our results may also contradict the increase 
in total HOAs that others have observed after WF-guided 
LASIK in hyperopes10 and support the decrease in total HOAs 
that has been observed after WF-optimized treatments.9,15 For 
both WF-guided and WF-optimized treated eyes, RMS error 
was lower at postoperative month 12 compared to baseline, 
but these improvements did not reach statistical significance 
(P=0.07, P=0.13, respectively). The trend observed in both 
groups may be due to increased corneal asphericity following 
hyperopic ablations, which render the cornea more prolate.
We randomized contralateral eyes to WF-guided and 
WF-optimized platforms because fellow eyes in the same 
individual are generally accepted to have more similar wound 
healing and corneal biomechanical properties than pairs of 
eyes from different individuals. Our use of the femtosecond 
laser may have had the effect of further reducing possible 
confounding variables. A recent meta-analysis comparing 
IntraLase to microkeratomes found no difference in efficacy 
or safety, but reported a statistically significant improvement 
in predictability with IntraLase (within ±0.50 D of target 
refraction).16 A second meta-analysis comparing femtosecond 
LASIK to mechanical microkeratome LASIK found no differ-
ence in efficacy, accuracy, or safety, but reported a statistically 
significant lower induction of total higher order aberrations 
and spherical aberration with femtosecond LASIK.17 Despite 
its strengths of being prospective, randomized, and having 
12 months of follow-up, our series had insufficient statistical 
power to make robust conclusions. The small size of our series 
may have also contributed to the potential bias introduced by 
a computerized randomization schedule, which despite being 
random, allocated a greater proportion of dominant eyes to 
the WF-guided group compared to the WF-optimized group 
(P=0.03). To assess the effect this may have had on our results, 
we conducted multivariate regression analyses for various 
outcome variables, including UDVA, CDVA, contrast sen-
sitivity, astigmatism, SE, RMS error, and subjective survey 
responses, with distance dominance and WF ablation modality 
(WF-guided vs WF-optimized) selected as predictor variables. 
The results of these analyses did not change our conclusions. 
Another potential limitation of this study was our omission 
of an angle kappa assessment from the initial patient evalu-
ation. If unrecognized, eyes with an angle kappa can result 
in ablations that are offset from the pupil center, and in turn, 
may in some cases affect refractive outcomes.
Based on this small, prospective comparative series of 
22 eyes, we conclude that WF-guided and WF-optimized 
LASIK performed on hyperopic patients with or without 
astigmatism can provide similar results for the parameters of 
safety, contrast sensitivity, and refractive error. It is possible 
that WF-guided treatments offer some advantages over WF-
optimized treatments, but this series lacked sufficient power 
to detect such differences if they were present. It will be of 
interest whether future studies with larger samples confirm 
our postulates, which should be interpreted with caution. Lon-
ger follow-up of this cohort may also prove instructive.
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